Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians
Rosella Spadi
World Journal of Clinical Oncology (2016) Vol. 7, Iss. 1, pp. 27-27
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos, Jörg Kleeff, Patrick Michl, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 6, pp. 333-348
Closed Access | Times Cited: 970
A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer
Yanyan Hu, Chongwei Chi, Shunhao Wang, et al.
Advanced Materials (2017) Vol. 29, Iss. 33
Closed Access | Times Cited: 99
Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation
Kai Qu, Xing Zhang, Ting Lin, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 89
Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine
Feifan Zhou, Jingxuan Yang, Yuqing Zhang, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 21, pp. 5335-5346
Open Access | Times Cited: 88
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells
Xiaolong Wei, Jiekun Yang, Sara J. Adair, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 45, pp. 28068-28079
Open Access | Times Cited: 67
Leptin-Notch signaling axis is involved in pancreatic cancer progression
Adriana Harbuzariu, Antonio Rampoldi, Danielle Daley-Brown, et al.
Oncotarget (2016) Vol. 8, Iss. 5, pp. 7740-7752
Open Access | Times Cited: 66
Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer
Demetrios Moris, Nikolaos Machairas, Diamantis I. Tsilimigras, et al.
Annals of Surgical Oncology (2019) Vol. 26, Iss. 6, pp. 1657-1668
Closed Access | Times Cited: 55
Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
Ching‐Yao Yang, Ming Huei Fan, Carol H. Miao, et al.
Molecular Therapy — Oncolytics (2020) Vol. 17, pp. 571-585
Open Access | Times Cited: 51
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
Susanna Hegewisch‐Becker, Ali Aldaoud, Thomas Wolf, et al.
International Journal of Cancer (2018) Vol. 144, Iss. 5, pp. 981-990
Open Access | Times Cited: 57
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
Serena Veschi, Laura De Lellis, Rosalba Florio, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 55
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
Ganji Purnachandra Nagaraju, Katerina Zakka, Jerome C. Landry, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 6, pp. 1529-1537
Open Access | Times Cited: 54
Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature
Sun-Young Jung, Cue Hyunkyu Lee, Hyang Sook Seol, et al.
Oncotarget (2016) Vol. 7, Iss. 38, pp. 62533-62546
Open Access | Times Cited: 51
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy
Claire Vennin, Nicola Rath, Marina Pajic, et al.
Small GTPases (2017) Vol. 11, Iss. 1, pp. 45-52
Open Access | Times Cited: 51
A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling
Zhe Pei, Wei Fu, Gongping Wang
Biochemical and Biophysical Research Communications (2017) Vol. 493, Iss. 1, pp. 455-460
Closed Access | Times Cited: 50
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Aesha I. Ali, Amanda J. Oliver, Tinaz Samiei, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 44
Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
Sriram Anbil, Michael Pigula, Huang‐Chiao Huang, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 6, pp. 1308-1319
Open Access | Times Cited: 41
scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis
Qijun Yi, Jie Wang, Tingting Liu, et al.
Cancer Letters (2023) Vol. 561, pp. 216149-216149
Closed Access | Times Cited: 14
Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells
Rosalba Florio, Barbara De Filippis, Serena Veschi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1977-1977
Open Access | Times Cited: 13
Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer
Metin Uz, Manisha Kalaga, Ramesh Pothuraju, et al.
Journal of Controlled Release (2018) Vol. 294, pp. 237-246
Open Access | Times Cited: 45
Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10
Louisa Stern, Nathalia A. Giese, Thilo Hackert, et al.
Journal of Cancer (2018) Vol. 9, Iss. 4, pp. 711-725
Open Access | Times Cited: 44
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei Fan, Xinyuan Xi, Surinder K. Batra, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 3, pp. 682-694
Open Access | Times Cited: 42
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
Avital Lev, Amriti R. Lulla, Jessica Wagner, et al.
Oncotarget (2017) Vol. 8, Iss. 47, pp. 81776-81793
Open Access | Times Cited: 41
Advances in oncolytic adenovirus therapy for pancreatic cancer
Callum Nattress, Gunnel Halldén
Cancer Letters (2018) Vol. 434, pp. 56-69
Open Access | Times Cited: 41
The function of microRNA related to cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Yaohui Fang, Chunlu Tan, Zhenjiang Zheng, et al.
Biochemical Pharmacology (2025) Vol. 236, pp. 116849-116849
Closed Access
Establishment of nomogram of early death in elderly pancreatic cancer patients with liver metastasis
Yang Wu, Li Tian, Runbing Zhang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top